Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Si-Bone Inc(SIBN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SIBN
09/24/2026: SIBN (2-star) is currently NOT-A-BUY. Pass it for now.
Si-Bone Inc is a growth-oriented medical device company recognized for its specialized, minimally invasive iFuse system that treats sacroiliac joint dysfunction. Its primary strength lies in its clinical evidence and dominant niche market position, which drives significant surgeon adoption. The company's main growth story centers on expanding its product portfolio into broader spinal fixation and penetrating global markets. However, investors must weigh these opportunities against intense competition from larger medical device firms, execution risks, and a history of operating losses. As the company seeks to scale toward profitability, it remains best suited for investors with a higher risk tolerance and a focus on long-term growth.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth medical device niche with significant potential for market expansion. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts strongly to positive clinical trial data and sales growth reports. |
| Value investor | Weak fit | The company is not currently valued based on traditional earnings or dividend metrics. |
| Dividend investor | Weak fit | Si-Bone does not pay a dividend as it remains in a growth and investment phase. |
| Low-risk investor | Weak fit | The stock carries high volatility and clinical/regulatory risks associated with a single-category medical device company. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to growth expectations and procedural volume fluctuations. |
| Valuation risk | Medium / high | Investors often pay a premium for growth, which can lead to corrections if growth slows. |
| Competition risk (Orthopedic/Spine giants) | Medium / high | Large incumbents with established hospital relationships and broad portfolios can challenge Si-Bone's market share. |
| Business quality | Medium | While the technology is validated, the company lacks the diversified revenue streams of larger medical device peers. |
| Dividend income | Low / none | The company provides no income to shareholders. |
| Execution risk | Medium | The business relies on successful surgeon education and continued positive reimbursement coverage. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -32.81% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 830.04M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 555.7K shares | Beta 0.7 | 52 Weeks Range 11.48 - 21.89 | Updated Date 09/24/2026 |
52 Weeks Range 11.48 - 21.89 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.33 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Implants and Instruments | Revenue from the sale of iFuse implants and specialized single-use instruments to hospitals and surgery centers. | The company earns money by selling specialized surgical kits that surgeons use to perform minimally invasive SI joint fusion. |
| Geography | Primary revenue is generated in the United States, with an emerging presence in select international markets. | Most of the company's business is currently based in the US, making it highly dependent on the US healthcare market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 731.38M | Price to Sales(TTM) 3.89 |
Enterprise Value 731.38M | Price to Sales(TTM) 3.89 | ||
Enterprise Value to Revenue 3.46 | Enterprise Value to EBITDA -14.15 | Shares Outstanding 44.82M | Shares Floating 39.99M |
Shares Outstanding 44.82M | Shares Floating 39.99M | ||
Percent Insiders 3.27 | Percent Institutions 109.54 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Si-Bone Inc
Exchange NASDAQ | Headquarters Santa Clara, CA, United States | ||
IPO Launch date 2018-10-17 | CEO & Director Ms. Laura A. Francis MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 376 | Website https://si-bone.com |
Full time employees 376 | Website https://si-bone.com | ||
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.